Neuraxpharm, a leading pharmaceutical company headquartered in Spain, is renowned for its commitment to improving the lives of patients with central nervous system (CNS) disorders. Founded in 1985, the company has established a strong presence across Europe, focusing on the development and distribution of innovative treatments for mental health conditions, including depression and anxiety.
With a diverse portfolio of products, Neuraxpharm stands out for its specialised formulations and patient-centric approach. The company has achieved significant milestones, including strategic acquisitions that have expanded its market reach and enhanced its product offerings. As a trusted name in the pharmaceutical industry, Neuraxpharm continues to prioritise research and development, solidifying its position as a key player in the CNS market.
-10 vs industry average
Neuraxpharm’s score of 28 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Neuraxpharm?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Neuraxpharm's reported carbon emissions
In 2024, Neuraxpharm reported total carbon emissions of approximately 119.1 million kg CO2e, comprising 2,052,450 kg CO2e from Scope 1, 1,966,500 kg CO2e from Scope 2, and a significant 115,117,310 kg CO2e from Scope 3 emissions. This marks an increase from 2023, where total emissions were about 117.2 million kg CO2e, with Scope 1 at 1,655,640 kg CO2e, Scope 2 at 1,757,390 kg CO2e, and Scope 3 at 113,801,360 kg CO2e. Neuraxpharm's emissions data is not cascaded from any parent company, indicating that these figures are independently reported. The company has not set specific reduction targets or initiatives as part of the Science Based Targets initiative (SBTi) or other climate pledges, reflecting a current lack of formal commitments to reduce emissions. Overall, Neuraxpharm's emissions profile highlights the significant impact of Scope 3 emissions, which constitute the majority of their carbon footprint, underscoring the need for comprehensive strategies to address these emissions in future sustainability efforts.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Neuraxpharm’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Neuraxpharm yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Neuraxpharm
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project